Revelation Biosciences (REVB) Accumulated Expenses (2020 - 2026)
Revelation Biosciences (REVB) posted quarterly Accumulated Expenses of $1.4 million for Q4 2025, up 23.68% year-over-year from $1.1 million in Q4 2024, and up 70.57% quarter-over-quarter from $819381.0 in Q3 2025.
Revelation Biosciences (REVB) Accumulated Expenses (2020 - 2026) Analysis & Trends
Revelation Biosciences (REVB) has reported Accumulated Expenses for 6 consecutive years, with $1.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Accumulated Expenses rose 23.68% year-over-year to $1.4 million; the TTM figure through Dec 2025 stood at $1.4 million (up 23.68% YoY), while the FY2025 annual figure was $1.4 million, up 23.68% from the prior year.
- Accumulated Expenses grew to $1.4 million in Q4 2025 per REVB's latest filing, from $819381.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $8.5 million in Q2 2024 and bottomed at $463632.0 in Q1 2025.
- Historically, Accumulated Expenses has averaged $1.6 million across 5 years, with a median of $996447.0 in 2022.
- Annual changes were most pronounced in 2021 — Accumulated Expenses surged 4426.44% — and 2025, when it tumbled 91.25%.
- Revelation Biosciences' Accumulated Expenses stood at $1.5 million in 2021, then tumbled by 35.53% to $985497.0 in 2022, then climbed by 16.94% to $1.2 million in 2023, then retreated by 1.94% to $1.1 million in 2024, then climbed by 23.68% to $1.4 million in 2025.
- Business Quant data shows REVB's Accumulated Expenses at $1.4 million in Q4 2025, $819381.0 in Q3 2025, and $739626.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Revelation Biosciences | 4.17 Mn | -7.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 759,937.00 |
| Dec 31, 2025 | 1.40 Mn |
| Sep 30, 2025 | 819,381.00 |
| Jun 30, 2025 | 739,626.00 |
| Mar 31, 2025 | 463,632.00 |
| Dec 31, 2024 | 1.13 Mn |
| Sep 30, 2024 | 934,372.00 |
| Jun 30, 2024 | 8.45 Mn |
| Mar 31, 2024 | 620,280.00 |
| Dec 31, 2023 | 1.15 Mn |
| Sep 30, 2023 | 1.02 Mn |
| Jun 30, 2023 | 496,870.00 |
| Mar 31, 2023 | 973,925.00 |
| Dec 31, 2022 | 985,497.00 |
| Sep 30, 2022 | 996,447.00 |
| Jun 30, 2022 | 2.17 Mn |
| Mar 31, 2022 | 3.71 Mn |
| Dec 31, 2021 | 1.53 Mn |
| Dec 31, 2020 | 33,772.00 |
| Sep 30, 2020 | 61,247.00 |